Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance

Go back to Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance

Tandem Diabetes Care (TNDM) PT Lowered to $35 at Citi

February 27, 2025 5:42 AM EST

Citi analyst Joanna Wuensch lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $35.00 (from $50.00) while maintaining a Buy rating.

The analyst comments "Tandem delivered 4Q24 revenue that was modestly higher than expectations, delivering $252.4M (up 20.6%) ahead of consensuss $249.7M,... More